Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.
Introduction
The treatment landscape of advanced neuroendocrine neoplasms (NENs) has dramatically evolved over the last decade. Somatostatin analogs (SSA), targeted drugs (everolimus and sunitinib), and, more recently, peptide receptor radionucleotide therapy (PRRT) have been approved for distinct subtypes of NENs [1] [2] [3] [4] [5] . Other treat-Neuroendocrinology 2019;108:18-25 DOI: 10.1159/000493319 ment options are available, including locoregional therapies in liver-predominant disease and systemic chemotherapy in more aggressive NENs [6] . Given the heterogeneity of the disease, therapy selection is still a challenge, even with approved drugs. Predictive markers are still lacking. While some treatments are safe, other treatments might be disadvantageous for patients not only for a lack of activity but deleterious side effects. The better knowledge of tumor heterogeneity, behavior, and prognosis of NENs has allowed a more precise classification and drug development plan in the metastatic setting. However, several issues are unresolved in the field of biomarkers, tools to best assess therapy response, and therapeutic choices.
The advisory board of the European Neuroendocrine Tumor Society (ENETS) discussed in their annual meeting which topics covering the unmet medical needs should be addressed in the metastatic setting and suggested several clinical and translational studies to solve these limitations. The current article summarizes the urgent limitations in different fields of a NENs setting, including biomarkers, disease behavior, imaging, and therapy.
Unmet Needs in the Biomarker Field
The search for biomarkers in oncology is mandatory to optimize therapy and to define prognostic tools for a better treatment management. General prognostic biomarkers are routinely used in clinical practice to guide treatment strategies in NENs, including differentiation and proliferation (measured by Ki67 index or mitotic count), tumor burden, hormone-related syndromes, or circulating biomarkers, such as chromogranin A or 5-HIAA (Table 1) . These tools are mainly used to define prognosis, but their utility to predict efficacy of therapies is limited.
Prospective validation of promising novel biomarkers, such as circulating tumor cells [7] and circulating tumor DNA, regarding their prognostic value is needed before implementing these tools in clinical practice. The feasibility of circulating tumor DNA compared to circulating tumor cells probably will position this approach for liquid biopsy in the near future [8] . The increasing use of circulating transcripts analysis (NETest) is showing additional data on different tumor types and therapies; even the real value compared with routine biomarkers, such as CgA, has been validated in small prospective cohorts and is investigated in ongoing clinical trials.
Proliferation and differentiation have also been assessed with the combination of tracers in the nuclear medicine theragnosis. Tumor heterogeneity is frequently shown by combining PET tracers, such as 18 FDG and 68 Ga-DOTA-SSA. The correlation of molecular tumor changes and translation to nuclear imaging could help to better define tumor heterogeneity and potentially guide therapeutic decisions.
The panel suggested several study proposals to define the possible role of new biomarkers in NENs, and the main ones are summarized in Table 2 .
Unmet Needs in the Imaging Field
The natural history of well-differentiated neuroendocrine tumors (NETs), with a usually slowly growing behavior, and the richness of vascularity as well as disease stabilization as best response to most therapies have always created a challenge in tumor assessment and response to therapy. The application of RECIST criteria assessing objective response in tumors with shrinkage of at least 30% of the tumor volume seems too rigorous for slowly growing NETs. Patients may benefit from targeted therapies even if best response is stabilization of the disease. Reevaluation of the sunitinib phase 2 and phase 3 clinical trial data recently suggested a 10% cutoff value for objective response as a better predictor of durable progression-free survival [11] . However, this threshold needs to be validated prospectively including other types of treatment. The use of Choi criteria has been discussed, since tumor shrinkage is combined with tumor attenuation measures and may depict some of the morphological changes that may occur with the use of targeted drugs, such as necrosis. Occurrence of large areas of hypodensity and/or necrosis has been described with the use of sunitinib and everolimus [12] . First data indicate that Choi criteria may add to early response prediction in advanced gastroenteropancreatic (GEP)-NENs treated with sunitinib [13] . Recent data from the phase IV study of sunitinib in pancreatic (Pan)-NETs showed a better estimation of progressionfree survival and overall response rate compared with RECIST criteria [14] . However, the value of Choi criteria needs to be validated prospectively in an integrated approach using modified RECIST criteria and Choi criteria.
The velocity of tumor growth has been defined as a prognostic tool and a critical value for the decision of initiation of systemic therapy with targeted agents or chemotherapy. The concept of tumor growth rate (TGR) has been retrospectively suggested as a valuable prognostic biomarker, and the changes of TGR have also been related to prolonged benefit of SSA [15] [16] [17] .
For the panel, 2 main issues should be urgently assessed regarding imaging procedures. Firstly, the TGR should be better defined by tumor type, location of metastases, and prediction of survival and response to therapy irrespective of the type of therapy. And secondly, radiological characteristics regardless of TGR should be uniformly standardized to avoid misunderstandings in tumor evaluation under specific therapies. The creation of clear criteria for tumor evaluation and different thresholds to predict response to each specific therapy should be of great interest. Table 3 summarizes a proposal for a retrospective study to validate TGR in different scenarios and radiological features to predict response and survival. 
Unmet Needs in Locoregional and Systemic Therapies
The natural history of the vast majority of NETs with high liver tropism of systemic disease has allowed during decades the combination or sequential application of locoregional liver therapies with systemic treatments. The limitation of active schedules to treat advanced disease has probably reinforced the intensive liver-directed approaches to reduce tumor volume and decrease hormone release and impact on the survival of patients. Fortunately, during the last decade, the armamentarium to treat systemic disease has significantly increased based on positive results of phase III clinical trials, and in advanced NETs, the use of several systemic therapies, including SSA, targeted agents, and PRRT, has demonstrated significant benefit in progression-free survival in different NETs locations.
It remains unclear if a locoregional therapy may impact the outcome of a patient to the same extent as a systemic therapy. Similarly, it has not been clarified if a sequential selection of specific drugs is superior to another sequence of drugs. None of the trials has shown an overall survival benefit, but this finding is probably confounded by a high cross-over rate in randomized placebo-controlled trials. Given the fact that none of the therapies provides cure, novel treatments are warranted. Thus, the panel discussion was focused on 3 main issues: the role of locoregional liver therapies compared with systemic treatments, the optimal sequence of available systemic therapies, and the future of new drugs in a NENs setting.
The experience of liver-directed therapies has been quite extensive during the last 3 decades with several reports showing radiological responses and clinical benefit. However, the lack of well-designed prospective and randomized clinical trials has limited the level of evidence of locoregional liver therapies in NETs. The arrival of new drugs in this setting based on positive results of phase III studies has increased the doubts of an optimal indication of liver-directed therapies, and we urgently need to create new evidence of the best scenarios for this treatment approach. Table 4 summarizes the main proposals discussed by the panel that could help to reduce the unmet needs in locoregional treatments.
Currently, systemic treatment options for advanced NENs are based on the results of prospective clinical studies in most of the indications. Regarding pancreatic origin, in addition to the streptozotocin-based chemotherapy approved for this indication in the US, SSA, everolimus, and sunitinib have demonstrated significant impact in controlling tumor progression compared with placebo in phase III studies. Recently, for small intestinal origin, everolimus and lutetium-177 DOTATATE have shown significant improvement of progression-free survival in advanced stages, and also everolimus has been the first drug to demonstrate an impact on progression-free survival in a phase III clinical trial including lung NETs. All these approved therapies need to be placed with other nonstandardized options, such as temozolomide-based chemotherapy or PRRT for primary tumors outside the small intestine, that exponentially increase the complexity of sequential therapies in advanced Pan-NETs or lung carcinoids.
One of the phase III clinical trials in a NENs setting that is recruiting patients nowadays is the SEQTOR study, an academic trial with the primary goal of assessing the sequence of established systemic therapies for Pan-NETs (streptozotocin-based chemotherapy and everolimus). Another trial comparing everolimus with PRRT in GEPNETs is the COMPETE study that recently started recruitment, as well as the French multicenter trial comparing PRRT and sunitinib in Pan-NETs (OCCLURANDOM). Several studies are comparing different treatment options for advanced disease; however, the real impact on surviv- al of sequential therapies that do not follow a rigorous scheme but may be highly variable depending on the accessibility of drugs and patient-related factors and comorbidities could only be assessed by prospective data or big data analysis from current clinical practice. Table 5 summarizes the proposal of the panel for a high-quality assessment of real-world data of sequential therapies in NETs.
Last but not least, a classical unmet need in oncology arrives when patients experience disease progression after all available treatment strategies have been employed. We are currently in the precision oncology era, but NENs are not the paradigm for this ambitious approach. The lack of clearly identified driver mutations has jeopardized the development of targeted agents with the same efficacy NEN, neuroendocrine neoplasm; Pan, pancreatic; SI, small intestinal; NET, neuroendocrine tumor; TAE/TACE, transarterial (chemo)embolization; PRRT, peptide receptor radionucleotide therapy; QoL, quality of life; PFS, progression-free survival. as observed in other tumor types, such as lung cancer or melanoma. Not only new drug development in a refractory setting is urgently needed, but also a better understanding of drug combinations is especially necessary for the NET field, where somatostatin analogues are probably too frequently used in combination with targeted agents or even with chemotherapy, with a lack of benefit demonstrated in prospective trials [18] . Some retrospective reports have suggested at least an additive effect of octreotide or lanreotide with everolimus or sunitinib [19] , even though these data have not been validated prospectively. Several clinical trials are currently recruiting patients and may clarify this issue in the near future. In the panel, 5 main unmet needs were profoundly discussed regarding the value of currently available drugs, drug combinations, and future development and are summarized in Table 6 . Finally, drug development has not been equally dedicated to all NET types or situations. Nowadays, for lung carcinoids, everolimus is the only drug approved so far, based on the results of a phase III clinical trial [20] . However, the most frequent first approach to treat advanced lung carcinoids is the use of SSA, even in the absence of prospective data in this setting and based only on retrospective cohorts that suggest a promising benefit of SSA mainly in typical carcinoids [21] . The SPINET (lanreotide vs. placebo) study is currently recruiting patients to answer this important question; however, the recruitment is significantly lower than expected, mainly because most patients receive somatostatin analogues "off label" upfront. The recommendation of the panel to solve this problem comes from 2 different points. Firstly, to prioritize the recruitment of patients in the SPINET study to clearly define the role of SSA in this setting; and secondly, foreseeing the long duration of expected recruitment and the time gap to make prospective data available, a highquality data collection of patients with lung carcinoids treated with SSA outside of a clinical trial could help in the final interpretation of the real value of this therapy. Further, chemotherapy (e.g., temozolomide) is frequently used as an additional treatment option, particularly in atypical carcinoids. Although a prospective phase 2 study is ongoing (ATLANT), gathering retrospective highquality data may help to understand the value of chemotherapy in lung carcinoids. In the same way, there are only retrospective data on PRRT in lung carcinoids, and its use cannot be widely recommended until a confirmatory prospective clinical trial will be available, so a global retrospective approach evaluating the activity of PRRT in this setting together with the best way to assess the somatostatin receptor expression in lung carcinoids should be a priority for the scientific community [22] .
The new WHO classification 2017 has included the expected group of G3 NETs, based on evidence of a clearly different behavior and response to chemotherapy compared with G3 neuroendocrine carcinomas. This discrimination of subgroups within the NEN G3 will be expanded to other anatomical sites in the near future. This new classification has clearly created a new orphan disease within NENs, and a treatment strategy for this new group is urgently needed. Data coming from prospective clinical trials will be very limited, and again high-quality data from routine practice would be extremely useful.
Conclusions
Unmet needs are frequent in medicine, especially in oncology, and even more in a complex, heterogeneous, and multidisciplinary disease such as NENs. The panel acknowledges the limitations of selecting some unmet needs and not others and of creating several proposals to try to resolve them. The field of discussion, advanced disease, is too broad to go into detail of all currently unmet needs, but efforts have been focused on 6 aspects that include the development of prognostic and predictive biomarkers, an optimization of the imaging assessment, a better understanding of the complexities of the disease, the development of high-quality retrospective studies that may complement the prospective ongoing trials and achieve faster results, an optimization of the available drugs and the design of future prospective trials, and, finally, a more accurate estimation of patients' quality of life and overall survival impact.
